selected publications
-
academic article
- A Phase I Protocol of Hydralazine and Valproic Acid in Advanced, Previously Treated Solid Cancers.. Translational oncology. :-. 2014
- A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcoma.. Cancers. 5:418-429. 2013
- A phase I study of 5-azacytidine and erlotinib in advanced solid tumor malignancies.. Cancer chemotherapy and pharmacology. 69:547-554. 2012
- Cytotoxic activity of the titanium alkoxide (OPy)(2)Ti(4AP)(2) against cancer colony forming cells.. Investigational new drugs. 30:114-120. 2012
- Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 23:785-790. 2012
- Phase I dose finding study of carboplatin, paclitaxel, and temozolomide in advanced solid tumors.. Melanoma research. 21:76-79. 2011
- Epidermal growth factor receptor as a biomarker for cervical cancer.. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO. 22:2166-2178. 2011
- A phase I study of flavopiridol in combination with gemcitabine and irinotecan in patients with metastatic cancer.. American journal of clinical oncology. 33:393-397. 2010
- GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancer.. Breast cancer research and treatment. 123:51-58. 2010
- Estrogen and progesterone receptor status and outcome in epithelial ovarian cancers and low malignant potential tumors.. Gynecologic oncology. 114:480-485. 2009
- GPR30 predicts poor survival for ovarian cancer.. Gynecologic oncology. 114:465-471. 2009
- Alternative administration of camptothecin analogues.. Expert opinion on drug delivery. 2:323-333. 2005
- TLK-286.. IDrugs : the investigational drugs journal. 7:771-781. 2004
- Phase II studies of antiangiogenic four drug regimens for the treatment of advanced renal cell carcinoma: FUNIL-retinoid and the FUNIL-thalidomide protocols.. Urologic oncology. 26:610-615.